Precise CRISPR-Cas9 Variants Come in Small Packages

GEN | October 01, 2019

The CRISPR-Cas9 protein from wild-type Staphylococcus aureus (SaCas9) is a diamond in the rough. The protein has potential because it is small—small enough to fit inside the adeno-associated virus (AAV), a vector commonly used to deliver genome editing components to living cells. Wild-type SaCas9, however, typically lacks high-genome-wide specificity. Consequently, a little cutting and polishing is needed if SaCas9 is to shine in genome editing applications. SaCas9 underwent cutting and polishing—that is, rational engineering—at the Ming Wai Lau Center for Reparative Medicine, a branch of the Karolinska Institutet in Hong Kong. This work, which was carried out by a scientific team led by Zongli Zheng, PhD, an assistant professor at the Karolinska Institutet, resulted in an SaCas9 variant called SaCas9-HF that is significantly more accurate than wild-type SaCas9.

Spotlight

To protect against such a fate, a suite of DNA-repairing proteins is on standby for when breaks occur. One of them is the evolutionarily conserved enzyme Dna2, which helps prepare broken DNA strands for repair by other proteins and also degrades excess pieces of DNA produced during replication.

Spotlight

To protect against such a fate, a suite of DNA-repairing proteins is on standby for when breaks occur. One of them is the evolutionarily conserved enzyme Dna2, which helps prepare broken DNA strands for repair by other proteins and also degrades excess pieces of DNA produced during replication.

Related News

RESEARCH

PharmAbcine to Present Updated Interim Data from the Ongoing Phase Ib Trial of Olinvacimab and Pembrolizumab Combination Therapy

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020. Positive data from the progressing security and tolerability study will feature wellbeing and certain viability information including ORR (Overall Response Rate) and DCR (Disease Control Rate) from 11 patients diagnosed with mTNBC. "We are excited to present highly encouraging data from our ongoing trial in the biggest breast cancer symposium. These data offer important insights into future development of the combo therapy," said Dr. Jin-San Yoo, CEO of PharmAbcine.

Read More

MEDICAL

Moderna Announces Supply Agreement with UK Government for Additional 2 Million Doses of mRNA-1273, Moderna’s Vaccine Candidate Against Covid-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to secure access to safe and effective COVID-19 vaccines by establishing a broad portfolio of the most promising vaccines. On November 16, Moderna reported that the autonomous, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 investigation of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Read More

Research Solutions Announces Partnership with BIO Business Solutions to Bring One-Click Scientific Literature Access to the Biotech Industry

Research Solutions | October 12, 2020

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform. Operated by the Biotechnology Innovation Organization (BIO), BIO Business Solutions is the industry's largest cost savings purchasing program. More than 4,500 member companies worldwide—including biotechnology and biopharmaceutical firms, medical device firms, academic institutions, state biotechnology centers, and related organizations—together save more than $511 million annually through the BIO Business Solutions® program.

Read More